About Synosia Therapeutics
Synosia Therapeutics is a company based in Basel (Switzerland) founded in 2005 was acquired by Biotie in January 2011.. Synosia Therapeutics has raised $91.16 million across 3 funding rounds from investors including UCB, Schroders and Investor. Synosia Therapeutics operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter Basel, Switzerland
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Synosia Therapeutics
Synosia Therapeutics has successfully raised a total of $91.16M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $30.0M
-
First Round
First Round
(05 Jan 2007)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2010 | Amount | Series C - Synosia Therapeutics | Valuation | UCB | |
| Jan, 2009 | Amount | Series B - Synosia Therapeutics | Valuation | Investor , Aravis | |
| Jan, 2007 | Amount | Series A - Synosia Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Synosia Therapeutics
Synosia Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include UCB, Schroders and Investor. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location | |
|
Venture capital fund backed incubator focused on the healthcare startups
|
Founded Year | Domain | Location | |
|
Investments are directed by the Wallenberg family into Nordic sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Synosia Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Synosia Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Synosia Therapeutics Comparisons
Competitors of Synosia Therapeutics
Synosia Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| domain | founded_year | HQ Location |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| domain | founded_year | HQ Location |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Synosia Therapeutics
When was Synosia Therapeutics founded?
Synosia Therapeutics was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Where is Synosia Therapeutics located?
Synosia Therapeutics is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Is Synosia Therapeutics a funded company?
Synosia Therapeutics is a funded company, having raised a total of $91.16M across 3 funding rounds to date. The company's 1st funding round was a Series A of $32.5M, raised on Jan 05, 2007.
What does Synosia Therapeutics do?
Synosia Therapeutics was established in 2005 in Basel, Switzerland, within the biotechnology sector. Focus is placed on developing pharmaceutical candidates for central nervous system disorders. The lead product, SYN-115, an adenosine A2a antagonist, is advanced for Parkinsons disease treatment. Additional candidates are pursued for Alzheimers disease, bipolar disorder, drug dependence, and post-traumatic stress disorder, with operations centered on research and clinical development.
Who are the top competitors of Synosia Therapeutics?
Synosia Therapeutics's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.
Who are Synosia Therapeutics's investors?
Synosia Therapeutics has 9 investors. Key investors include UCB, Schroders, Investor, Abingworth, and Biotie.